This study assesses the cost-effectiveness of adding a sodium-glucose cotransporter 2 inhibitor versus switching to a glucagon-like peptide-1 receptor agonist in patients with diabetes on metformin and a dipeptidyl peptidase-4 inhibitor.
Julia F. Slejko, PhD
Advertisement
Articles by Julia F. Slejko, PhD
Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
emtelligent Turns Unstructured Clinical Data Into Actionable Insights
2
Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD
5